Key facts
- RawRx’s last known valuation is $910K (Jan 2025).
- It has raised $170K; the latest was Early Stage VC ($170K) in Jan 2025.
- Notable investors include JITO Incubation & Innovation Foundation, Silver Surfer Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for RawRx
- ·The full record, as it builds
Funding rounds
No funding rounds for RawRx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RawRx
Producer of food-based supplements intended to solve health issues through preventive care. The company offers a wide range of products, such as multivitamins, vitamin sleep lotions, calcium tablets, and more, that are made with nutritional resources, enabling customers to get appropriate food-based supplements and live a healthy life.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Kolkata, India
- Founded
- 2021
- Employees
- 2
- Website
- rawrx.in/
- Ownership
- Privately Held (backing)
RawRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RawRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RawRx in its N-PORT filings yet. We sweep new filings monthly.